Targeted radiation therapy for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these cancers that has spread or returned: prostate, colorectal, lung (non-small cell or small cell), head and neck, ovarian, cervical, endometrial, triple-negative breast, or esophageal.
- Your cancer must have gotten worse despite treatment, and you must have run out of standard options that are likely to help.
- You must have at least one tumor that can be measured on a scan.
- You must be able to care for yourself (ECOG score 0-2) and have a life expectancy of at least 4 months.
- If you are of childbearing age, you must agree to use effective birth control and not be pregnant or breastfeeding.
- If you have liver metastases, they must be small and few in number.
- If you have triple-negative breast cancer, your tumor must be confirmed negative for estrogen, progesterone, and HER2 receptors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
This early-stage trial tests a new radioactive drug (177Lu-FC516) designed to target and treat prostate cancer that has spread and is no longer responding to standard treatments. The goal is to evaluate whether it is safe and effective.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.